Biosynthetic Gene Clusters of Astragalus Triterpenoid Saponins: From Genome Discovery to Synthetic Biology and Biomanufacturing Prospects

Astragaloside IV is the best-characterized cycloartane-type triterpenoid saponin and the pharmacopoeial quality marker of Astragali Radix, with documented cardioprotective, antitumor, and immunomodulatory effects. Supply is constrained by long cultivation cycles that vary with production practice, replant disease, and phytochemical variability. Six representative genome assemblies are summarized for the genus, and they show that triterpenoid tailoring genes are partly, but not universally, clustered: a ~4 Mb biosynthetic gene cluster houses the oxidative and glycosylating enzymes, whereas the backbone synthase gene AmOSC3 lies outside it. The core route from 2,3-oxidosqualene to astragaloside IV has been reconstituted enzyme by enzyme; the in planta downstream routing, the acetylation steps forming astragalosides I and II, and the regulation, compartmentalization, transport, and storage of these saponins remain unresolved. Heterologous production is at the proof-of-concept stage: 1.04 mg/L cycloastragenol in yeast (versus the 25 g/L artemisinic acid precedent), 2.224 mg astragaloside IV/g dry weight in Nicotiana benthamiana, and a 4.2-fold total-astragaloside increase in AmUGT15-overexpressing hairy roots. This review consolidates genome mining, pathway biochemistry, and synthetic-biology engineering; benchmarks current platforms against pharmacopoeial quality requirements; and maps the bottlenecks between proof of concept and sustainable biomanufacturing.